-
Mashup Score: 0IMS 2023 | VJHemOnc - 7 month(s) ago
The 20th International Myeloma Society (IMS) Annual Meeting was held in Athens, Greece, from 27-30 September, 2023. This meeting focused on the latest basic, preclinical, and clinical advances in the field of multiple myeloma. The 20th International Myeloma Society (IMS) Annual Meeting was held in Athens, Greece, from 27-30 September, 2023. This meeting focused on the latest basic, preclinical, and clinical advances in the field of multiple
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study - 7 month(s) ago
#TAPUR results of pembrolizumab in various tumors with HTMB extend KEYNOTE-158 data that led to FDA approval in tumors with HTMB
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17 - 7 month(s) ago
PURPOSE The integration of immunotherapy in the perioperative setting of muscle-invasive urothelial carcinoma (MIUC) appears promising. SAKK 06/17 investigated the addition of neoadjuvant durvalumab to gemcitabine/cisplatin (GC) chemotherapy followed by radical surgery and adjuvant checkpoint inhibition with durvalumab. PATIENTS AND METHODS SAKK 06/17 was an investigator-initiated, open-label, single-arm phase II study including cisplatin-fit patients with stage cT2-T4a cN0-1 operable MIUC. Four cycles of neoadjuvant GC in combination with four cycles of durvalumab (start with GC cycle 2) were administered, followed by radical surgery. Adjuvant durvalumab was given for 10 cycles. The primary end point was event-free survival (EFS) at 2 years. RESULTS Sixty one patients were accrued at 12 sites. The full analysis set consisted of 57 patients, 54 (95%) had bladder cancer. Median follow-up was 40 months. The primary end point was met, with EFS at 2 years of 76% (one-sided 90% CI [lower bo
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Byoung Chul Cho, MD, PhD, Yonsei University College of Medicine, Seoul, South Korea, provides an overview of findings from the Phase II EVOKE-02 trial (NCT05186974) of sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate (ADC), and pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Patients were divided into two cohorts, where cohort A consisted of patients with a PD-L1 tumor proportion score (TPS) of more than 50%, and cohort B consisted of patients with a PD-L1 TPS of less than 50%. The investigational regimen showed promising safety and efficacy in both cohorts, and a higher overall response rate was observed in cohort A. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
PURPOSE The Atezo-Brain study evaluated atezolizumab combined with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) with untreated brain metastases, a population traditionally excluded from trials. METHODS This single-arm phase II clinical trial enrolled patients with advanced nonsquamous NSCLC with untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment. Dexamethasone was allowed up to 4 mg once daily. Atezolizumab plus carboplatin and pemetrexed was given for four to six cycles followed by atezolizumab plus pemetrexed until progression for a maximum of 2 years. The primary end points were to determine the progression-free survival (PFS) rate at 12 weeks and the incidence of grade ≥3 adverse events during the first 9 weeks. Intracranial outcomes were assessed using response assessment in neuro-oncology brain metastases criteria. RESULTS Forty patients were enrolled and 22 (55%) were receiving corticosteroids at baseline. T
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Outcomes of I-SABR in lung cancer - 7 month(s) ago
Joe Chang, MD, PhD, The University of Texas MD Anderson Cancer Centre, Houston, Texas, comments on the efficacy of stereotactic ablative radiotherapy (SABR) alongside immunotherapy (I-SABR) in the treatment of lung cancer. Many patients with lung cancer develop secondary malignancies that are undetectable through circulating tumour (ct)-DNA analysis. Consequently, immunotherapy is an important second-line treatment to reduce the recurrence of cancer and treat microscopic malignancies. Prof. Chang shares that high dose I-SABR has been shown to have a dramatic effect on reducing the recurrence of lung cancer, hence immunotherapy can be effective in this clinical setting. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Joshua Richter, MD, Mount Sinai Medical Center, New York City, NY, comments on the recent approval of teclistamab for the treatment of relapsed/refractory (R/R) multiple myeloma, emphasizing the value of this agent in the R/R space. Dr Richter also discusses the importance of preventing toxicities with this agent and further summarizes various strategies being followed to mitigate these toxicities. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJHemOnc – The video journal of hematological oncology - 7 month(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We've had some lovely interviews so far at #IMS23 and many more to go! 🎉 Stay tuned as we continue to share our content on https://t.co/O9p0vDBrzw! @Myeloma_Society #MMsm #HemOnc #ImmunoOnc https://t.co/HwnM6nnhoE
-
-
Mashup Score: 0Vaccination in Multiple Myeloma: Review of Current Literature - 7 month(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Vaccination in Multiple Myeloma: Review of Current Literature [Jun 8, 2016] Alemu, Richards, Oaks, @mtmdphd CLML https://t.co/bhwKr0nDDw #mmsm #ImmunoOnc #IDonc https://t.co/5rB5mcSFAz
-
Vaccination in Multiple Myeloma: Review of Current Literature [Jun 8, 2016] Alemu et al. @mtmdphd CLML https://t.co/bhwKr0nDDw #mmsm #ImmunoOnc #IDonc https://t.co/s8O0qZr6Gk
-
-
Mashup Score: 7Vitamin D receptor upregulation in alloreactive human T cells - 7 month(s) ago
Vitamin D deficiency is adversely associated with diseases characterized by inflammation. The combination of the high incidence of vitamin D deficienc…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
Missed out on #IMS23? Don’t worry! We’ve got all you need - check out our expert interviews here: 👉 https://t.co/0ZcFKvFI09 #MMsm #HemOnc #ImmunoOnc #CARTcell https://t.co/PJ3s43oTc0